

TABLE OF CONTENTS

| | |
|---|-----|
| Preface..... | iii |
| Disclosure of Potential Conflicts of Interest..... | iv |
| Continuing Pharmacy Education and Program Instructions..... | v |

| | |
|----------------------|---|
| Endocrinology I..... | 1 |
|----------------------|---|

GUIDELINES AND TREATMENT

OF HYPERGLYCEMIA

*By Krystal L. Edwards, Pharm.D., FCCP, BCPS; and
Lisa M. Chastain, Pharm.D., BCACP, BCPS*

| | |
|---|----|
| Learning Objectives..... | 3 |
| Introduction..... | 3 |
| National Guidelines and Algorithms..... | 3 |
| Baseline Knowledge Statements..... | 3 |
| Additional Readings..... | 3 |
| Abbreviations in This Chapter..... | 4 |
| Early Insulin Initiation..... | 8 |
| Treatment Controversies and Concerns..... | 9 |
| New and Emerging Therapies..... | 13 |
| Bariatric Surgical Treatment..... | 17 |
| Conclusion..... | 19 |
| Self-Assessment Questions..... | 22 |

DIABETES-RELATED COMPLICATIONS

By Debra A. Lopez, Pharm.D., BCACP, BCPS, CDE

| | |
|------------------------------------|----|
| Learning Objectives..... | 27 |
| Introduction..... | 27 |
| Baseline Knowledge Statements..... | 27 |
| Additional Readings..... | 27 |
| Acute Complications..... | 28 |
| Abbreviations in This Chapter..... | 28 |
| Microvascular Complications..... | 31 |
| Macrovascular Complications..... | 36 |
| Other Complications..... | 39 |
| Conclusion..... | 40 |
| References..... | 41 |
| Self-Assessment Questions..... | 45 |

DIABETES PRACTICE MANAGEMENT

*By Matthew W. Strum, Pharm.D., BCACP, CDE;
and Jessica M. Bellone, Pharm.D., BCACP*

| | |
|---|----|
| Learning Objectives..... | 49 |
| Introduction..... | 49 |
| Baseline Knowledge Statements..... | 49 |
| Additional Readings..... | 49 |
| Diabetes Self-Management Education and Training..... | 50 |
| Abbreviations in This Chapter..... | 50 |
| Transitions in Care: Childhood to Geriatric Diabetes..... | 57 |
| Communication and Documentation..... | 60 |
| Billing..... | 62 |

| | |
|--------------------------------|----|
| Conclusion..... | 64 |
| References..... | 64 |
| Self-Assessment Questions..... | 67 |

OBESITY AND METABOLIC SYNDROME

*By Kathryn M. Hurren, Pharm.D., BCACP; and
Marissa Waldman Dunham, Pharm.D., BCPS*

| | |
|------------------------------------|----|
| Learning Objectives..... | 72 |
| Introduction..... | 72 |
| Baseline Knowledge Statements..... | 72 |
| Additional Readings..... | 72 |
| Pathophysiology..... | 73 |
| Abbreviations in This Chapter..... | 73 |
| Drug-Induced Weight Gain..... | 74 |
| Patient Assessment..... | 74 |
| Treatment..... | 75 |
| Conclusion..... | 84 |
| References..... | 84 |
| Self-Assessment Questions..... | 86 |

| | |
|-----------------------|----|
| ENDOCRINOLOGY II..... | 90 |
|-----------------------|----|

ADRENAL AND PITUITARY DISORDERS

*By Steven M. Smith, Pharm.D., MPH, BCPS; and
Katherine Vogel Anderson, Pharm.D., BCACP*

| | |
|------------------------------------|-----|
| Learning Objectives..... | 92 |
| Adrenal Disorders..... | 92 |
| Baseline Knowledge Statements..... | 92 |
| Additional Readings..... | 92 |
| Abbreviations in This Chapter..... | 93 |
| Pituitary Disorders..... | 108 |
| Conclusion..... | 113 |
| References..... | 113 |
| Self-Assessment Questions..... | 117 |

THYROID AND PARATHYROID DISORDERS

By Eric Schneider, Pharm.D., BCPS

| | |
|------------------------------------|-----|
| Learning Objectives..... | 121 |
| Introduction..... | 121 |
| Baseline Knowledge Statements..... | 121 |
| Additional Readings..... | 121 |
| Thyroid Disorders..... | 122 |
| Abbreviations in This Chapter..... | 122 |
| Parathyroid Disorders..... | 135 |
| Conclusion..... | 139 |
| References..... | 139 |
| Self-Assessment Questions..... | 143 |

HYPOGONADISM

By Daniel M. Riche, Pharm.D., BCPS, CDE;
and Justin J. Sherman, Pharm.D., MCS

| | |
|---|-----|
| Learning Objectives | 147 |
| Introduction | 147 |
| Baseline Knowledge Statements | 147 |
| Additional Readings | 147 |
| Physiology and Classification | 148 |
| Clinical Presentation and Diagnosis | 148 |
| Abbreviations in This Chapter | 148 |
| Testosterone Replacement Therapy | 150 |
| Latest Studies | 158 |
| Conclusion | 159 |
| References | 159 |
| Self-Assessment Questions | 162 |

| | |
|---------------------|-----|
| Rheumatology I..... | 167 |
|---------------------|-----|

GOUT AND HYPERURICEMIA

By Jessica F. Farrell, Pharm.D.

| | |
|---|-----|
| Learning Objectives | 169 |
| Introduction | 169 |
| Baseline Knowledge Statements | 169 |
| Additional Readings | 169 |
| Pathophysiology | 170 |
| Clinical Findings | 170 |
| Abbreviations in This Chapter | 170 |
| Diagnosis | 172 |
| Treatment Overview | 172 |
| Prognosis | 181 |
| Outcomes | 181 |
| Patient Education | 181 |
| Management of Comorbid Conditions | 181 |
| Conclusion | 182 |
| References | 182 |
| Self-Assessment Questions | 185 |

RHEUMATOID ARTHRITIS

By Susan P. Bruce, Pharm.D., BCPS

| | |
|-------------------------------------|-----|
| Learning Objectives | 190 |
| Introduction | 190 |
| Pathophysiology | 190 |
| Baseline Knowledge Statements | 190 |
| Additional Readings | 190 |
| Abbreviations in This Chapter..... | 191 |
| Diagnosis and Prognosis | 192 |
| Comorbid Conditions | 192 |
| Treatment | 194 |
| Patient Education | 199 |
| Quality Improvement | 200 |
| Conclusion..... | 201 |
| References | 201 |
| Self-Assessment Questions | 204 |

SYSTEMIC LUPUS ERYTHEMATOSUS

By Jennifer N. Clements, Pharm.D., BCPS, CDE

| | |
|--------------------------------------|-----|
| Learning Objectives | 210 |
| Introduction | 210 |
| Baseline Knowledge Statements | 210 |
| Additional Readings..... | 210 |
| Epidemiology | 211 |
| Etiology | 211 |
| Abbreviations in This Chapter | 211 |
| Pathophysiology | 213 |
| Diagnosis | 214 |
| Treatment | 215 |
| Other Issues | 222 |
| Patient Outcomes and Prognosis | 227 |
| Conclusion | 227 |
| References | 227 |
| Self-Assessment Questions | 231 |